Thomas F Gajewski

USPTO Granted Patents = 13 (Patent Applications = 9)

EPO Patents = 4 (Patent Applications = 7)

Average Co-Inventor Count = 2.5

ph-index = 4

Forward Citations = 85(Granted Patents)

Company Filing History:

11 out of 915

The University of Chicago

patents

1 out of 349

Arch Development Corporation

patents

1 out of 832,812

Other

patents

Years Active: 2000-2024

Loading Chart...

13 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11946936 - Beta-catenin inhibitors in cancer immunotherapy (2024-04-02),

2. 11802316 - Methods and compositions related to T-cell activity (2023-10-31),

3. 11638728 - Microbiome biomarkers immunotherapy responsiveness: diagnostic, prognostic and therapeutic uses thereof (2023-05-02),

4. 11566077 - Dysfunctional antigen-specific CD8T cells in the tumor microenvironment (2023-01-31),

5. 10967060 - Synergistic combination of immunologic inhibitors for the treatment of cancer (2021-04-06),

6. 10815531 - Methods and compositions related to T-cell activity (2020-10-27),

7. 10753938 - Beta-catenin inhibitors in cancer immunotherapy (2020-08-25),

8. 10034939 - Synergistic combination of immunologic inhibitors for the treatment of cancer (2018-07-31),

9. 9944992 - Methods and compositions related to T-cell activity (2018-04-17),

10. 9855302 - Treatment of cancer by manipulation of commensal microflora (2018-01-02),

11. 7381401 - T cell anergy is reversed by active Ras and regulated by diacylglycerol kinase (2008-06-03),

12. 6716422 - Vaccine adjuvants for immunotherapy of melanoma (2004-04-06),

13. 6080399 - Vaccine adjuvants for immunotherapy of melanoma (2000-06-27),

Title: Thomas F. Gajewski: Innovator in Cancer Immunotherapy

Introduction

Thomas F. Gajewski is a prominent inventor based in Chicago, IL (US), known for his significant contributions to cancer immunotherapy. With a total of 13 patents, Gajewski has made remarkable strides in understanding and combating cancer through innovative methods and compositions.

Latest Patents

Among his latest patents, Gajewski has developed compositions and methods for the treatment of cancer by inhibiting β-catenin or a β-catenin pathway. These inventions focus on employing inhibitors of β-catenin and/or the Wnt/β-catenin signaling pathway to prevent or reverse the evasion of immune responses or immunotherapy by cancers. Additionally, he has worked on methods and compositions related to anergic T-cells in patients, particularly cancer patients, enhancing the understanding of T-cell activity in immunotherapy.

Career Highlights

Gajewski has had a distinguished career, working at the University of Chicago, where he has contributed to groundbreaking research in cancer treatment. His work has been pivotal in advancing the field of immunotherapy, providing new avenues for treatment options for cancer patients.

Collaborations

Throughout his career, Gajewski has collaborated with notable colleagues, including Stefani Spranger and Yan Zheng, further enriching the research landscape in cancer immunotherapy.

Conclusion

Thomas F. Gajewski's innovative work in cancer immunotherapy has made a significant impact on the field, showcasing the importance of research and collaboration in developing effective treatments for cancer. His contributions continue to inspire advancements in medical science.

This text is generated by artificial intelligence and may not be accurate.